sepia officinalis (sepia) golyócskák
dr. peithner kg gmbh&co -
sepia officinalis (sepia) golyócskák
dr. peithner kg gmbh&co -
sepia officinalis golyócskák
dr. peithner budapest kft. -
sepia officinalis (sepia) golyócskák
remedia homöopathie gmbh -
sepia officinalis (sepia) golyócskák
remedia homöopathie gmbh -
olumiant
eli lilly nederland b.v. - baricitinib - arthritis, rheumatoid - immunszuppresszánsok - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). az olumiant monoterápiában vagy metotrexáttal kombinációban alkalmazható. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.
blincyto
amgen europe b.v. - blinatumomab - prekurzorsejt limfoblasztikus leukémia-limfóma - daganatellenes szerek - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
xigris
eli lilly nederland b.v. - alfa drotrekogin (aktivált) - sepsis; multiple organ failure - antitrombotikus szerek - a xigris a súlyos szepszisben szenvedő, többszörös szervi elégtelenségben szenvedő felnőtt betegek kezelésére javallott, ha azt a legjobb standard ellátáshoz adják. a xigris alkalmazását főként olyan esetekben kell figyelembe venni, amikor a kezelés megkezdődik a szervi elégtelenség kialakulását követő 24 órán belül (további információkért lásd az 5. pontot.
bendamustine accord 2,5 mg/ml por oldatos infúzióhoz való koncentrátumhoz
accord healthcare polska sp. z o.o. - bendamustine-hidroklorid-monohidrát -
bendamustine accord 25 mg/ml koncentrátum oldatos infúzióhoz
accord healthcare polska sp. z o.o. - bendamustine-hidroklorid-monohidrát -